^
Association details:
Biomarker:CCND1 overexpression
Cancer:Breast Cancer
Drug:veliparib (ABT-888) (PARP inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Published date:
11/17/2020
Excerpt:
...high Cyclin D1 predicted non-response in VC, control, and AMG386...High levels of Cyclin D1, but not other cell cycle proteins, predict non-response to chemo-/targeted-therapy across arms and subtypes,…
Secondary therapy:
carboplatin
Trial ID: